Undifferentiated carcinoma
MONDO:0005617A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.
Also known as: anaplastic carcinoma, carcinoma, undifferentiated, carcinoma, undifferentiated, malignant, undifferentiated carcinoma
2824 clinical trials for this condition and its sub-types, 6 tagged with Undifferentiated carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Undifferentiated carcinoma
-
Undifferentiated ovarian carcinoma 13 trials
-
Nut midline carcinoma 6 trials
-
Sinonasal undifferentiated carcinoma 6 trials
-
1 sub-type
-
Salivary gland large cell carcinoma 0 trials
-
Thymic undifferentiated carcinoma 0 trials
-
New drug cocktails show promise against tough endometrial cancer
Disease control OngoingThis study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control OngoingThis study tests whether combining two drugs, cediranib and olaparib, works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum-based chemo. About 582 women will be randomly assign…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC